Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.87 |
| ▸ | CNR2 | P34972 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.87 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.50 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2218546 | 1.00 | CNR1 (0.87) | CNR1CNR2ALDH1A1LPAR1LPAR2 | |
| Water SCHEMBL11118961 | 0.98 | CNR1 (0.84) | CNR1CNR2ALDH1A1LPAR1LPAR2 | |
| SCHEMBL12023406 | 0.95 | CNR1 (0.97) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL4645046 | 0.95 | CNR1 (0.97) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL495999 | 0.93 | CNR1 (1.00) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL496000 | 0.93 | CNR1 (1.00) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL3690975 | 0.93 | CNR1 (1.00) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL632823 | 0.91 | CNR1 (0.73) | CNR1CNR2ALDH1A1LPAR1LPAR3 | |
| SCHEMBL24208055 | 0.90 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR2 | |
| SCHEMBL10492075 | 0.90 | CNR1 (0.71) | CNR1CNR2ALDH1A1LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5023135-A | — | — | None | — | — | JP | disclosed |
| US-20250288622-A1 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | WAGENINGEN UNIVERSITEIT (NL) | 2025-09-18 | — | — | US | disclosed |
| US-20250288621-A1 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | COMPAGNIE GERVAIS DANONE (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12371401-B2 | Dithienyl disulfiram derivatives as selective ALDH1A1 inhibitors | BATTERJEE MEDICAL COLLEGE (SA) | 2025-07-29 | — | — | US | disclosed |
| EP-3967315-B1 | AKKERMANSIA MUCINIPHILA FOR TREATING CANCER | UNIV CATHOLIQUE LOUVAIN (BE) | 2025-05-14 | — | — | EP | disclosed |
| US-20250145565-A1 | DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS | BATTERJEE MEDICAL COLLEGE (SA) | 2025-05-08 | — | — | US | disclosed |
| EP-3862010-B1 | USE OF AKKERMANSIA MUCINIPHILA FOR PROMOTING WEIGHT LOSS | UNIV CATHOLIQUE LOUVAIN (BE) | 2025-05-07 | — | — | EP | disclosed |
| EP-4512479-A2 | UTILISATION D'AKKERMANSIA POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES | Université Catholique de Louvain (BE) | 2025-02-26 | — | — | EP | disclosed |
| EP-4509182-A2 | UTILISATION D'AKKERMANSIA POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES | Université Catholique de Louvain (BE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4509181-A2 | UTILISATION D'AKKERMANSIA POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES | Université Catholique de Louvain (BE) | 2025-02-19 | — | — | EP | disclosed |
| EP-1291376-B1 | SILICONE POLYMER, SILICONE COMPOSITION, AND COSMETIC PREPARATION CONTAINING THE SAME | SHINETSU CHEMICAL CO (JP) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009064696-A1 | STEROL-MODIFIED AMPHIPHILIC LIPIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-22 | — | — | WO | disclosed |
| CN-101410128-A | Use of probiotic micro-organisms for the treatment and prevention of obesity and related disorders | DANISCO (DK) | 2009-04-15 | — | — | CN | disclosed |
| EP-1981516-A2 | USE OF PROBIOTIC MICROORGANISMS FOR THE TREATMENT AND PREVENTION OF OBESITY AND RELATED DISORDERS | Danisco A/S (DK) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085970-A2 | USE OF PROBIOTIC MICROORGANISMS FOR THE TREATMENT AND PREVENTION OF OBESITY AND RELATED DISORDERS | DANISCO A/S (DK) | 2007-08-02 | — | — | WO | disclosed |
| EP-1291376-A1 | SILICONE POLYMER, SILICONE COMPOSITION, AND COSMETIC PREPARATION CONTAINING THE SAME | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2003-03-12 | — | — | EP | disclosed |
| US-5607970-A | GLYCEROL MONOSTEARATE OR PALMITATE | KABUSHIKI KAISYA ADVANCE (JP) | 1997-03-04 | — | — | US | disclosed |
| WO-1996023811-A1 | SITOSTEROL- AND ACYLGLYCEROL-BASED ORGANOMETALLIC COMPLEXES, AND PHARMACEUTICAL COMPOSITIONS AND DIET PRODUCTS CONTAINING SAME | MAUREL SANTE (FR) | 1996-08-08 | — | — | WO | disclosed |
| EP-0549804-A1 | ACAT INHIBITOR | KABUSHIKI KAISYA ADVANCE (JP) | 1993-07-07 | — | — | EP | disclosed |
| JP-H0523135-A | ACAT INHIBITOR | ADVANCE CO LTD | 1993-02-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371401-B2 | Dithienyl disulfiram derivatives as selective ALDH1A1 inhibitors | ALDH3A1, ALDH1A1, ADH1A | CNR1 3432/4885CNR2 3303/4885ALDH1A1 2/4885 |
| US-20250145565-A1 | DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS | ALDH3A1, ALDH1A1, ADH1A | CNR1 3432/4885CNR2 3303/4885ALDH1A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.